Moteur de recherche d’entreprises européennes
Financement de l’UE (150 000 €) : Profilage quantitatif de biomarqueurs protéiques hautement multiplexé (hmqPro) Hor01/07/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Profilage quantitatif de biomarqueurs protéiques hautement multiplexé (hmqPro)
The project will develop a multipurpose, highly multiplexed, quantitative protein profiling (hmqPro) platform that can be adapted to a wide range of applications, particularly biomarker discovery. Biomarkers are a 43 Billion USD market spanning applications in diagnostics, drug discovery & development, personalized medicine, disease risk assessment. The method comprises an antibody-based profiling of a large number of proteins or protein posttranslational modifications against a large number of samples irrespective of source. Unlike competitor methods, hmqPro does not require platform-specific assay or detection equipment. Dual multiplexing implemented in a variant method, hmqPro-2D, will make the platform competitive against existing protein profiling methods in per-assay cost, flexibility and scalability. The hmqPro platform uniquely complements the technology portfolio of Epigenica AB and we will chart out two commercialization routes: first, hmqPro will be integrated into a service laboratory offering high-throughput sample-to-result epigenome and protein profiling services to academia, pharma and biotech industries. Second, we will package the method in a kit format distributed to R&D and clinical end users. In summary, the proposed project will deliver a new quantitative protein profiling platform that will have the capacity to impact the biomarker discovery market by combining unique flexibility with high-throughput.
| Epigenica AB | 120 000 € |
| Karolinska Institutet | 30 000 € |
https://cordis.europa.eu/project/id/101069454
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.